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Abstract
Background: Identifying new approaches to tuberculosis treatment that are effective and put less
demand to meagre health resources is important. One such approach is community based direct
observed treatment (DOT). The purpose of the study was to determine the cost and cost
effectiveness of health facility and community based directly observed treatment of tuberculosis in
an urban setting in Tanzania.
Methods:  Two alternative strategies were compared: health facility based directly observed
treatment by health personnel and community based directly observed treatment by treatment
supervisors. Costs were analysed from the perspective of health services, patients and community
in the year 2002 in US $ using standard methods. Treatment outcomes were obtained from a
randomised-controlled trial which was conducted alongside the cost study. Smear positive, smear
negative and extra-pulmonary TB patients were included. Cost-effectiveness was calculated as the
cost per patient successfully treated.
Results: The total cost of treating a patient with conventional health facility based DOT and
community based DOT were $ 145 and $ 94 respectively. Community based DOT reduced cost
by 35%. Cost fell by 27% for health services and 72% for patients. When smear positive and smear
negative patients were considered separately, community DOT was associated with 45% and 19%
reduction of the costs respectively. Patients used about $ 43 to follow their medication to health
facility which is equivalent to their monthly income. Indirect costs were as important as direct
costs, contributing to about 49% of the total patient's cost. The main reason for reduced cost was
fewer number of visits to the TB clinic. Community based DOT was more cost-effective at $ 128
per patient successfully treated compared to $ 203 for a patient successfully treated with health
facility based DOT.
Conclusion: Community based DOT presents an economically attractive option to complement
health facility based DOT. This is particularly important in settings where TB clinics are working
beyond capacity under limited resources.
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Background
Tuberculosis (TB) is among the top ten causes of global
mortality and morbidity accounting for about 26% of all
preventable deaths [1,2]. In Tanzania, more than 60,000
new TB patients are notified annually and TB is the third
leading killer of adults behind Malaria and Acquired
Immune-deficiency syndrome (AIDS) [3,4]. The rapid
annual increase of TB cases in the country is largely attrib-
uted to Human immunodeficiency Virus (HIV).
The importance of TB/HIV co-infection as a major public
health problem in Tanzania is not only due to its high
incidence and mortality but also to its social and eco-
nomic consequences. Tanzania is one of the several coun-
tries experiencing a reversal in human development
mainly due HIV/AIDS and TB epidemics [5]. The majority
of people with TB/HIV co infection are in the economic
productive age group and the World Bank estimates that
the gross domestic product (GDP) will be 15–20% lower
in 2015 than it would have been without the AIDS pan-
demic [3,5].
The internationally recommended DOTS (Directly
Observed Treatment-short course) strategy has been
implemented in the country for more than 18 years
mainly in public health facilities with treatment directly
observed by trained health staff. However, fewer than half
of all health facilities in the country provide TB services.
Efforts to expand DOTS to more health facilities have
been limited by scarce resources and understaffing. This
leads to overcrowding of patients especially in urban set-
tings like Dar es Salaam, which notify about a quarter of
all TB patients in the country. The rising number of TB
cases and critical shortage of skilled staff has put consider-
able strain on the public health system. With a public
health budget of about US $ 6 per capita per year, the TB
epidemic significantly influences the Tanzanian health
system performance. Therefore, identifying new
approaches to treatment that maintain effectiveness and
put less demands to the meagre health resources by reduc-
ing pressure and lowering cost of delivering TB treatment
becomes a priority. One such approach is community
based direct observed treatment (DOT).
Supervision of TB patients in the community has been
piloted in a variety of settings with successful results [6-9].
However, little is known about the cost and cost effective-
ness of this option in Tanzania. The economic analysis is
important to assist policy makers in decision making and
rational allocation of scarce health resources. We con-
ducted the study to determine the cost and cost effective-
ness of health facility and community based DOT in an
urban setting in Tanzania.
Methods
Study setting
The study was conducted in Temeke district in Dar es
Salaam city. Temeke is an urban district with low socio-
economic indicators characterised by rapid population
growth and overburdened public health services. The dis-
trict has a population of about 700,000 people with a
health facility to population ratio of about 1 per 5000.
Tuberculosis and AIDS are leading causes of death in the
district, representing 36.5% of years of life lost for all age
groups [10].
Alternative strategies
Two treatment options were compared; health facility
based DOT option and community based DOT option
using treatment supervisors. A brief description of the
alternatives is given below, as full details are available
elsewhere [6].
The conventional (health facility based DOT) approach to
tuberculosis control in Tanzania presupposes initial diag-
nosis and treatment of patients on ambulatory basis, pro-
vided the patients are strong enough to follow their
medication and are free from complications that need
hospital care[11]. During the intensive two months
period, patients visit health facility daily for direct obser-
vation of treatment by trained health personnel. This is
followed by a 6-month continuation phase period where
patients visit a health facility once per month. Before 2003
and during the study period, smear negative and extra pul-
monary TB patients received intermittent drug regimen
three times weekly. Currently all patients receive daily
treatment
In the new treatment option (community based DOT)
direct observation of treatment was supervised by treat-
ment supervisors rather than health facility personnel as
in the conventional treatment. The supervisors were
guardians and former TB patients. A guardian was defined
as a family member or a close relative living with patient.
Patients were assisted in the selection of a responsible,
trusted guardian. Willing former TB patients who had suc-
cessfully completed treatment and lived close to the
patients' home were selected by the district tuberculosis
and leprosy co-ordinators (DTLC). Treatment supervisors
collected drugs from health facilities once per week during
the entire two months intensive period. During this
period a health worker also made surprise visits to
patients' homes to check for adherence of treatment by
reviewing treatment cards and pill count. Patients were
also requested to report to the TB clinics fortnightly for
clinical evaluation and monitoring of their progress. After
the first two months, treatment was exactly as in the con-
ventional health facility option.Cost Effectiveness and Resource Allocation 2005, 3:6 http://www.resource-allocation.com/content/3/1/6
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Study participants
The study was conducted alongside a randomised-con-
trolled study [6]. To select patients to be included in this
study, a systematic sampling method was used. A list of all
patients who participated in the randomised trial was
drawn from the TB registers. Patients were listed consecu-
tively as they appeared in the TB register. Separate lists
were prepared for patients who received community DOT
and health facility DOT. From the lists every fifth patient
was picked to participate in the present study. The corre-
sponding supervisors of the patients allocated to commu-
nity DOT were also interviewed. The study population
consisted of tuberculosis patients over 5 years old who
started treatment in the district. New smear positive and
smear negative pulmonary tuberculosis as well as extra
pulmonary tuberculosis patients were included in the
study. Patients were excluded from the study, if they had
been previously treated for TB and if they had severe ill-
ness that precluded ambulatory treatment. Patients were
recruited from five diagnostic centres in the district with
high caseload (more than 100 patients per year). The
study was conducted between December, 2001 and Janu-
ary 2003.
Costing
Costs were assessed from a societal perspective as advo-
cated by current standards for cost-effectiveness analysis
[12-14]. Average costs of each component of care and
treatment was calculated as the quantity of resources used
multiplied with their unit price. Costs associated with
diagnosis were not included in the analysis, since
approaches to diagnosis were the same for all options.
Furthermore, costs associated with TB diagnosis would
have been difficult to accurately establish because of the
long delays in diagnosis and the fact that these costs were
incurred before TB was confirmed. The exclusion of the
cost of diagnosis in the study does not however influence
the relative ranking of community DOT and health facility
based DOT, but means that comparison with other health
interventions such as malaria control cannot be done.
Broadly, the costs were categorised as "provider" and "per-
sonal" or "community". Provider cost is associated with
developing and operating a health care service. They
include staff costs, supplies and equipment. Provider's
costs were incurred by the health system, tuberculosis pro-
gramme and the community TB project. Personal or com-
munity costs are those incurred by patients and treatment
supervisors. They include direct and indirect costs. Direct
costs are non-medical costs related to visiting the TB clinic
such as transport costs, buying food and drinks when vis-
iting a TB clinic. Direct medical costs such as drug costs are
included as provider's costs because they were incurred by
the TB programme. Indirect costs refer to the value of lost
time by the patients and treatment supervisors to follow
up TB treatment. This should not be confused with over-
heads of fixed costs used in accounting practices as
pointed by some authors [12].
Costs of a visit to a TB clinic were calculated from one
health facility (Mbagala) in Temeke. Joint costs (costs
items which were used for more than one activity) were
allocated according to the proportion of the time the cost
item was used for TB activity. Capital costs were annual-
ised using a discount rate of 10%. This has been used in
other studies in Tanzania and has been recommended by
the Bank of Tanzania in 2002 [15,16]. Annualisation was
done on the assumption that the expected useful life of
buildings was 30 years, for vehicles and equipment 10
years and for motorcycles 5 years. The base year for valu-
ing costs was 2002, and exchange rate applicable at that
time was 967 Tanzanian Shillings to US $1.
Sources of data included budget and expenditure files for
Temeke district, health facilities, the community TB
project in Temeke and the National Tuberculosis and Lep-
rosy Programme (NTLP). Others include salary scales for
established positions, reports from Temeke municipal,
Ministry of Health and the Bank of Tanzania. Face to face
interviews were conducted with the staff of the health
facilities, Temeke Municipal and Ministry of Health.
Patients costs were estimated using a structured question-
naire. Patients were interviewed about travel and time
costs associated with a visit to the TB clinic, their average
monthly income and other costs associated with TB treat-
ment and care. Time costs were converted to a monetary
value based on the average reported income among inter-
viewed patients (including all sources of incomes). Costs
incurred by the treatment supervisors were assessed by a
structured questionnaire by asking about the time and
travel costs to collect drugs as well as supervising a patient
to take medication, and other costs (incurred) including
training and supervision of community DOT. Costs per
patients treated in different treatment options (commu-
nity VS health facility) were calculated as a weighted aver-
age of the costs according to TB type (smear positive,
smear negative and extrapulmonary)
Effectiveness
Measure of effectiveness used was treatment success. Data
on treatment outcomes were obtained from the ran-
domised-controlled trial and operational definitions used
in this study are explained in detail elsewhere [6]. Briefly,
treatment success included patients who were cured and
those who completed treatment. Cured patients were
those with positive sputum smear before starting treat-
ment and confirmed to be sputum negative at 7(or 8)
months and at least one previous occasion. Completed
treatment applied to: patients who had positive pre-treat-Cost Effectiveness and Resource Allocation 2005, 3:6 http://www.resource-allocation.com/content/3/1/6
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ment results, negative results at 2 months, and no end of
treatment results; patients who had negative pre-treat-
ment results and had been placed on treatment for clinical
reasons, and patients who completed the full course of
treatment, but had no pre-treatment or end-of-treatment
bacteriological results.
The term treatment success is used in routine practice to
refer to smear positive patients who are cured and have
completed treatment. It is worth noting that we have
expanded this definition to include smear negative and
extra pulmonary tuberculosis patients who completed
treatment as well, since our aim is to compare alternative
treatment strategies regardless of the patient's TB type.
This operational definition has also been used by other
researchers [17].
Estimates of cure rate that would apply without treatment
(null intervention scenario) was calculated assuming a
self cure rate of 20% in the absence of treatment for indi-
viduals who are not otherwise immuno-compromised,
and a self cure rate of 0% for those who are HIV+[13,18].
This can be calculated from the formula: {(estimated per-
centage of patients who are HIV + x 0) + (estimated per-
centage of patients who are HIV- x 20) }/100
Cost-effectiveness
Cost effectiveness was calculated as the average cost per
patient treated successfully. This was done by dividing the
total cost and patients successfully treated.
Sensitivity analysis
One way sensitivity analyses were undertaken to assess the
robustness of the results to changes in key input variables.
The uncertainty analyses were based on most likely, min-
imum and maximum values. For valuing time cost, aver-
age reported income of the patients was used as the base-
case estimates. Sensitivity analysis was conducted when
time was valued as zero for all patients and when time was
valued for patients with income only. For the effectiveness
data, lower and upper boundaries of 95% confidence
interval of the treatment outcome was used. Sensitivity
analysis was undertaken with and without 'no treatment
'option (Table 3)
Results
Study participants
A total of 103 TB patients and 42 treatment supervisors
were enrolled in the study. Among the patients 45 (44%)
received DOT in the community and 58 (56%) received
DOT in health facility. The majority of the patients were
male 63 (61%) and the mean age of the patients was 32
years (median 30). Most of the patients 67 (65%)
Table 1: General characteristics of the patients
Community DOT n (%) Health facility DOT n (%)
Sex
Male 26 (57.8) 37 (63.8)
Female 19 (42.2) 21 (36.2)
Age (in years)
Mean (SD) 31 (9) 33 (12)
Education status
No education 5 (11.1) 4 (6.9)
Not completed primary school 9 (20.0) 7 (12.1)
Completed primary school 25 (55.6) 42(72.4)
Secondary school and above 6 (13.3) 4 (6.9)
Others 0 1(1.7)
Occupation
Informal and self employed 21 (46.7) 22 (37.9)
Employed 14 (31.1) 14 (24.1)
No employment 5 (11.1) 7 (12.1)
Housewife 5 (11.1) 15 (25.9)
Home-TB clinic distance
Below 1 km 29 (64.4) 46 (79.3)
1–2 kms 10 (22.2) 7 (12.1)
Above 2 kms 6 (13.3) 5 (8.6)
TB type
Smear- positive PTB 25 (55.6) 33 (56.9)
Smear- negative PTB and extra-pulmonary TB 20 (44.4) 25 (43.1)Cost Effectiveness and Resource Allocation 2005, 3:6 http://www.resource-allocation.com/content/3/1/6
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completed primary education and worked in informal
sector or self-employed 43 (42%). The average reported
income of the patients was USD 43. No significant differ-
ence (p > 0.05) was found between patients treated in
community and health facilities on social-demographic
variables (Table 1). The majority of the treatment supervi-
sors were guardians (39, 91%) and females (27, 63%).
Their mean age was 37 years (SD 12, median 38).
Table 2: Average cost per patient for different items of alternative DOT options
Health facility DOT Community DOT
Provider's cost Smear positive Smear 
negative&EPTB
Total 
health 
facility 
USD*
Smear positive Smear 
negative&EPTB
Total 
community 
USD*
quantity Unit 
price 
USD
quantity Unit 
price 
USD
quantity Unit 
price 
USD
quantity Unit 
price 
USD
Visit TB clinic 58 1.12 24 1.90 56.0 10 1.12 10 1.90 15.0
Drugs 1 20.90 1 12.10 17.0 1 20.90 1 12.10 17.0
NTLP management & supervision district 
level
11 . 5 0 11 . 5 0 1.5 11 . 5 0 11 . 5 0 1.50
NTLP management & supervision 
regional level
10 . 9 3 10 . 9 3 0.9 10 . 9 3 10 . 9 3 0.90
Community project management 1 26.97 1 26.97 27.0 1 26.97 1 26.97 27.0
Community project supervision 1 13.16 1 13.16 13.0
Community project training 1 0.90 1 0.90 0.9
Total providers cost 102 75
Patient's cost
Direct 58 0.51 24 0.51 22.0 10 0.51 10 0.51 5.0
Indirect 58 0.50 24 0.51 21.0 17 . 5 4 15 . 9 0 7.0
Total patient's cost 43 12
Treatment supporter's cost
Direct 80 . 2 4 80 . 2 4 1.92
Indirect 16 . 1 8 14 . 5 4 5.43
Total treatment supporter's cost 7
Total cost 145 94
*Weighted average of smear positives(56%) and smear negatives and extra- pulmonary (44%)
Table 3: Influence of changes in key input variables on cost-effectiveness ratio in US $ per patient successful treated
Input variable Input value Average CER community DOTa Average CER health facility DOTa
Min. Max. Min. Max. Min. Max.
Patient time lossb 0 US$0.29 117 130 168 203
Supporter time lossb 0 US $ 0.48 123 129 196 196
Discount rate 0 3% 125 125 186 188
Success rate(community DOT)c 69% 78% 136 120
Success rate (health facility DOT)c 62% 74% 281 235
Success rate(community DOT)d 81% 89% 116 106
Success rate (health facility DOT)d 79% 87% 184 167
aThe sensitivity analyses are based on base-case calculations
btime loss: minimum=assuming time is valued as zero; maximum= average income per hour among those with income only
cSuccess rate taking in consideration cure rate in 'no treatment' scenario
dSuccess rate without cure rate in 'no treatment' scenarioCost Effectiveness and Resource Allocation 2005, 3:6 http://www.resource-allocation.com/content/3/1/6
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Costs
The average cost of treating patients under the alternative
DOT options is shown in figure 1. Overall, treating a
patient under community DOT was less costly by 35%
compared to health facility based DOT. The total cost of
treating a patient under health facility DOT was US 145
compared to USD 94 for treating a patient under commu-
nity DOT. Costs were reduced from all perspectives: pro-
viders (TB programme and community project) and
community (patients and treatment supervisors). Com-
munity DOT reduced providers cost by 27%, patients cost
by 72%, and combined patients and treatment supporter
cost (community cost) by 55%.
Providers cost was about 70% (USD 102) of the total
health facility DOT cost compared to 80 %(USD 75) of
community DOT total cost (Table 2). A visit to the TB
clinic was the main cost item of health facility DOT, con-
stituting about 55% (USD 56) of the providers cost. This
cost item included all recurrent and capital clinic costs
excluding drugs and investigations. Overall management
and supervision was the main cost item under community
based DOT constituting to about 53% (USD 40) of pro-
viders cost (Table 2).
Patients costs was about 30% (USD 43) of all health facil-
ity DOT cost compared 13 % (USD 12) of community
DOT cost. The combined patients and treatment supervi-
sors cost (community cost) was 20 %(USD 19) of all cost
under the community DOT option (Figure 1 and Table 2).
Indirect patients cost under health facility DOT was as
important as direct cost, accounting for about 49% of
patients' cost. Indirect cost was attributed mainly to the
time lost from work. Patients lost an average of 2 hours
daily to follow up TB treatment in the health facility.
Separate analysis of the cost according to TB type, showed
a marked reduction in total cost among smear positive
patients treated under community DOT compared to
smear negative and extra pulmonary treated under the
same option. Cost fell by 45% and 19% respectively (Fig-
ures 2 and 3).
Effectiveness
A total of 587 patients were recruited to study the effec-
tiveness of TB treatment. Among them 260 were ran-
domised to community based DOT and 327 to health
facility based DOT. Both DOT options gave similar
Average cost per patient (all patients) Figure 1
Average cost per patient (all patients).
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treatment outcomes. Treatment success rates among
patients under community and health facility based DOT
were 85 %(221 patients) and 83 %(271 patients) respec-
tively (OR 1.17, 95% CI 0.75–1.83) [6]. The upper and
lower confidence intervals for treatment success in com-
munity DOT were 89% and 81% while that of the patients
in health facility DOT were 87% and 79%. For smear pos-
itive patients the cure rates were 78% for community
based patients and 79% for health facility based patients.
Given, HIV prevalence among TB patients in Tanzania of
44% [19], and using the formula to calculate cure rate
without treatment, it is estimated that, about 11.2% of
patients will be cured without TB treatment. When taking
into consideration the 'no treatment' scenario, the treat-
ment successes are 74% and 72% for community and
health facility based DOT patients respectively.
Cost-effectiveness
Figure 4, shows cost-effectiveness of patients treated
under community DOT and health facility based DOT.
Community based DOT was more cost effective with USD
128 per patient successfully treated, compared to USD
203 for patient successfully treated with health facility
DOT. The implementation of community based DOT has
improved cost-effectiveness by 37%. For smear positive
patients, Community based DOT was cost effective with
USD 145 per patient cured while health facility was USD
258 per patient cured. Community based DOT improved
cost effectiveness by 44% among smear positive patients.
Sensitivity analysis
The sensitivity analysis revealed that changes in key input
variables did not change the cost-effectiveness ratio of
community based DOT in favour of health facility based
DOT. Community based DOT remained less costly and
more cost-effective (Table 3)
Discussion
The key finding of this study was that community based
DOT was less costly and more cost effective compared to
health facility based DOT. This was true from all perspec-
tives: provider's, patients' and treatment supervisors'.
Community based DOT maintained programme
effectiveness and improved cost-effectiveness by 37%.
Implementation of community based DOT reduced cost
of treating a patient by one third. This implies that with
same level of resources, more TB patients can be success-
fully treated.
The main reason for the substantial reduction of cost
under community DOT was fewer number of visits to the
TB clinic. A smear positive patient under health facility
DOT made a total of 58 visits to a health facility while a
smear negative and extra-pulmonary patient had a total of
24 visits. On the other hand, a patient under community
DOT made a total of 10 visits.
The study has a number of limitations, emanating from
methodological and operational issues. First, since the
study aimed at determining the costs and cost effective-
ness of DOT options regardless of the smear status, we
combined treatment outcomes and cost data of smear
positive, smear negative and extra pulmonary TB patients.
In routine practice, the treatment outcomes are reported
separately. This may have disproportionately underesti-
mated the cost of treating a smear positive patient under
health facility compared to community DOT because,
smear negative and extra pulmonary patients under
health facility DOT had fewer visits to the TB clinic than
smear positives. On the other hand all patients under
community DOT had the same number of visits. How-
ever, this could not have changed the conclusion of the
study since community based DOT remained the less
costly option even after these assumptions were tested in
sensitivity analysis. Furthermore, patients' treatment out-
come and cost data were analysed separately according to
TB type and presented as weighted average in the final
analysis.
Second, the analysis focussed only on the direct benefit of
TB treatment to the individual being treated. We calcu-
lated neither the secondary benefit of TB treatment
accrued by reduction of transmission in the community
nor indirect benefit of community based treatment to the
community. Treatment of TB has been shown to have
secondary benefit by averting three deaths for every case of
TB cured [20]. By considering the benefit of treatment
only to the index case, our estimates of the benefit of TB
are conservative. However, quantifying the secondary
Average cost per patient successfully treated under alterna- tive DOT options Figure 4
Average cost per patient successfully treated under alterna-
tive DOT options.
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benefits of TB treatment involves complex assumptions,
and the inclusion of smear negative and extra pulmonary
TB patients would have made such calculations more dif-
ficult. Moreover, since TB treatment is already considered
an important health intervention [21], and implemented
throughout Tanzania, our main interest was to determine
cost-effectiveness of alternative TB treatment delivery
options.
Finally, health facility cost information was obtained
from only one out of five health facilities studied. How-
ever, patients and treatment supervisors data were col-
lected from all five-health facilities. The chosen health
facility was viewed as broadly representative of the other
health facilities in the district providing TB services.
Furthermore the health facility had good record keeping
of budget and financial details.
Indirect cost in the study has been estimated from time
lost due to a visit to TB clinic. There is no agreement
among experts on proper way of measuring and valuing
indirect cost due to lost time [12-14,22]. We used average
reported income among TB patients as baseline value of
indirect cost due to lost time. The disadvantage of this
method is that it may overestimate or underestimate costs
[13]. However, sensitivity analysis was conducted when
indirect cost due to lost time was valued to zero and when
indirect cost was valued among people with income only.
This did not change cost-effectiveness ratio in favour of
alternative option.
The main strength of the study is that costing was con-
ducted prospectively alongside a randomised-controlled
trial. Quantification and analysis of cost and effectiveness
information was carried out in real time and the two
groups in the alternative options were comparable.
Although TB services in Tanzania are provided free of
charge to the patients, the study showed that patients
incurred considerable cost to follow their treatment at the
health facility. Patients cost were 30% of the total cost,
amounting to $ 43. This is equivalent to their monthly
average reported income. These costs did not include
expenses used for seeking diagnosis, which have been
shown by other studies to be substantial [23,24]. Worth
noting also is the fact that indirect costs contributed to
about 49% of the total patient's cost.
The findings that community DOT is less costly and more
cost effective both from providers and community per-
spective is consistent with studies conducted elsewhere
[25]. Community DOT reduced cost in our study by 35%.
Studies in Malawi and Kenya showed that community
DOT reduced cost by 50% and 65% respectively [26,27].
Cost reduction was much higher in these settings than in
our study. The main reason given is reduction in hospital
stay. This is not surprising since we did not include hospi-
talised TB patients in our study. In Tanzania TB patients
are treated on ambulatory basis and admitted only when
they are seriously sick.
In order to implement community based DOT, additional
cost for initial investments has to be incurred. These
include cost for activities such as community supervision
and management. This constituted about 53% of provid-
ers cost under the community based DOT option. The
increased investment, which is minor in absolute term, is
nevertheless offset in the long run by savings accrued by
implementation of community DOT.
Community based DOT has the potential of increasing
the number of TB patients treated without significantly
increase in resources. With annual reported TB cases of
about 4000, it can plausibly assumed that 2000 more TB
patients could be successfully treated in Temeke district,
using the current level of resources. This might have wider
policy implications in Tanzania and beyond. If commu-
nity DOT is less costly and is not in any way inferior to
conventional health facility treatment, the question is
how relevant are these results in other areas beyond the
study area. Temeke district represents the growing chal-
lenge of controlling TB in urban settings where the num-
bers of TB patients are increasing and the health system is
over-stretched. Our findings should be broadly generalis-
able in similar settings, since the cost of main items such
as staff and drugs are fairly standard. The health facility
costs are generally comparable across the country as
shown in previous studies [4,15]. The main determinants
of patients' cost are not different in many urban centres.
The extent to which these findings can be generalised to
rural areas is debatable. Evidence suggests that commu-
nity based DOT is effective even in these settings [7].
Whether it is cost-effective as well is uncertain. The main
factors for patients cost; low-income levels and greater dis-
tance to health facilities are different from urban settings.
Therefore, potential difficulties with widespread imple-
mentation of this model must not be underestimated.
Conclusion
Community DOT presents an economically attractive
option to complement health facility based DOT. It
improves the affordability and cost-effectiveness of TB
treatment. Community DOT might also help to reduce
congestion in TB clinics, which are increasingly overbur-
dened by the rising number of patients. This is particularly
important in urban centres where TB clinics are working
beyond capacity. TB programmes need to consider com-
munity DOT as an economically sound and viable option
and implement it in the framework of routine programme
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